IPV-102 Safety, Tolerability and Immunogenicity of TAK-195 in Healthy Infants, Toddlers and Adults

NCT03092791 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

340

Enrollment

INDUSTRY

Sponsor class

Stopped Planned immunogenicity outcomes not reached

Conditions

Poliomyelitis

Interventions

BIOLOGICAL: Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)
BIOLOGICAL: Reference IPV
BIOLOGICAL: sIPV Placebo

Sponsor

Takeda